# Harmony Biosciences Holdings Inc. (HRMY) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $42.25, market value $2.5 billion.

## Valuation
- **P/E (trailing): 13.7×** (5-yr avg 27.0×, 3-yr avg 14.2×). Harmony Biosciences Holdings Inc. trades at 13.7× trailing earnings, well below its own five-year average of 27.0×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 6.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.79**. A PEG of 0.79 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.6×**. Each dollar of revenue is priced at 2.6×.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 7.3%**. The inverse of the P/E: 7.3% of the price is earned each year.

## Profitability
- **Gross margin: 75.4%**. Harmony Biosciences Holdings Inc. keeps 75.4% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 24.0%**. 24.0% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 18.3%**. 18.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 18.2%**. 18.2% on shareholders' equity is solid.
- **Return on invested capital: 64.8%**. Return on all capital, debt included, is 64.8%: comfortably above what that capital costs.
- **Return on assets: 14.3%**. Each dollar of assets produces 14.3% of profit.

## Growth
- **Revenue growth (1 yr): 21.5%** (3-yr 25.6%/yr, 5-yr 40.3%/yr). Revenue grew 21.5% over the last year, against 40.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 8.0%** (3-yr -3.0%/yr). Earnings per share rose 8.0%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 34.1%/yr**. Free cash flow has compounded at 34.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.19**. Debt is 0.19 times equity: a conservative balance sheet.
- **Altman Z-score: 5.86**. A Z-score of 5.86 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Harmony Biosciences Holdings Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (11 analysts). 11 analysts cover Harmony Biosciences Holdings Inc.; the consensus is buy, with an average price target of $47.36 (+12% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 16.4%** (YTD 12.9%, 3-mo 31.2%). The shares are up 16.4% over twelve months including dividends.
- **From 52-week high: -2.9%** (65.6% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 66**. An RSI of 66 is neutral.
- **Beta (1 yr): 0.55** (volatility 45%). Beta of 0.55 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HRMY · Page: https://foliofundamentals.com/stocks/hrmy

Not investment advice.